Helping families share hereditary cancer risk information and access genetic testing
Testing Effectiveness of Navigation Interventions to Increase Uptake of Cascade Genetic Testing Among Relatives of Individuals Diagnosed With Hereditary Cancer Syndromes
This project tries web-based navigation and communication tools to help adults with a known hereditary cancer gene and their adult biological relatives share risk information and make it easier for relatives to get genetic testing.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Michigan Rogel Cancer Center Academic / other |
| Locations | 1 site (Ann Arbor, Michigan) |
| Trial ID | NCT06927947 on ClinicalTrials.gov |
What this trial studies
This interventional effort uses a virtual Cascade Genetic Testing Platform to deliver web-based communication, educational materials, and navigation support to probands with a confirmed pathogenic germline variant and their adult biological relatives. Probands must have been evaluated at the University of Michigan Cancer Genetics Clinic; relatives must be adults, English-speaking, have internet access, and not have completed clinical germline testing. The platform aims to overcome logistic and communication barriers that limit cascade testing uptake, with outcomes measured over a shortened 6-month follow-up. Participants complete surveys and use informational/communication tools designed to increase relatives' participation in genetic testing and follow-up with genetics providers.
Who should consider this trial
Good fit: Ideal candidates are adults who carry a clinically confirmed autosomal dominant pathogenic germline variant identified through the University of Michigan Cancer Genetics Clinic and their adult biological relatives who have not had genetic testing and have internet access and English proficiency.
Not a fit: People who already completed clinical germline genetic testing, who are not biological relatives, who lack internet access, or who cannot read/speak English are unlikely to receive benefit from this intervention.
Why it matters
Potential benefit: If successful, this approach could increase the number of at-risk relatives who learn their genetic status and take preventive or management steps.
How similar studies have performed: Previous cascade-testing efforts show modest baseline uptake (about 20–30%), and some navigation or web-based interventions have produced incremental gains, but fully virtual cascade platforms are still relatively new.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * PROBANDS: Clinically confirmed autosomal dominant pathogenic germline variant (PGV) associated with a hereditary cancer syndrome * PROBANDS: Previous evaluation by the University of Michigan (U-M) Cancer Genetics Clinic * PROBANDS: ≥ 18 years old * PROBANDS: Able to speak and read English * PROBANDS: Access to the internet * RELATIVES: Biological relative of proband * RELATIVES: ≥ 18 years old * RELATIVES: Able to speak and read English * RELATIVES: Access to the internet * RELATIVES: Have not completed germline genetic testing, per self-report at baseline Exclusion Criteria: * RELATIVES: Prior clinical germline genetic testing for cancer or already have an upcoming appointment scheduled with a genetics provider, per self-report at baseline
Where this trial is running
Ann Arbor, Michigan
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States (Recruiting)
Study contacts
- Principal investigator: Elena M Stoffel — University of Michigan Rogel Cancer Center
- Study coordinator: MiGHT HelpLine
- Email: MiGHT-Cascade@med.umich.edu
- Phone: (734) 764-4044
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.